Bruker Corporation (BRKR)
OvervaluedFundamental
33
Price
$62.65
Market Cap
$9.87B
Part 1 · What the company is worth
Overview
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. The company offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools; innovative nuclear magnetic resonance (NMR) and electron paramagnetic resonance (EPR) products; solutions for in-vivo processes and drug discovery; aftermarket solutions; solutions for lab automation and digitalization; mass spectrometry solution and test kits, DNA test strips, and fluorescence-based PCR technologies; genotype and fluorotype molecular diagnostics kits; and research, analytical, and process analysis instruments and solutions. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; services for transcriptional profiling and multiomic analysis; superconducting materials, such as metallic low temperature superconductors; multifilament round and rectangular LTS wires in both monolithic and wire-in-channel formats; designs and manufactures Cuponal; metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation was founded in 1960 and is headquartered in Billerica, Massachusetts.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on September 18, 2026 with claude-haiku-4-5 — shared with all users
Named by Bruker in its own 10-K, Thermo Fisher sells mass spectrometers, molecular spectroscopy and electron microscopy systems to the same pharmaceutical, academic and industrial laboratories Bruker serves worldwide.
Agilent competes head-on in mass spectrometry, chromatography coupling and molecular spectroscopy for life-science and applied-chemistry labs, the core of Bruker's CALID business.
Waters sells LC-MS platforms to the same pharmaceutical QC, proteomics and food-safety customers that buy Bruker's timsTOF and triple-quadrupole instruments.
Through SCIEX and Leica Microsystems, Danaher bids against Bruker for the same mass-spectrometry and high-end microscopy budgets in research and clinical laboratories.
Shimadzu offers a full analytical-instrument catalogue — mass spectrometry, spectrophotometry, surface analysis — and is Bruker's main Japanese rival in Asian academic and industrial accounts.
JEOL is the main alternative supplier of NMR and electron-microscopy systems, the market where Bruker's BioSpin division holds its strongest position.
Balance Sheet & Liquidity
Revenue
$3.50B
Trailing 12 months (through 6/30/2026)
Net Income
$-71M
Trailing 12 months (through 6/30/2026)
Free Cash Flow
$43M
Total Equity
$2.46B
Total Liabilities
$3.73B
Current Ratio
1.85
Interest Coverage
0.50
Debt/EBITDA
6.33
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$46.11
Current Price
$62.65
Margin of Safety
-35.9%
Fair Value Range
$29.97 - $62.25
Spread across the valuation methods used, not a statistically calibrated confidence interval.
Estimation Methods
Valuation Metrics
P/E Ratio
-
ROE
-0.4%
P/B Ratio
4.11
P/FCF
105.06
Gross Margin
46.4%
ROIC
-0.5%
Profitability Radar
Value Creation (Economic Moat)
ROIC
-0.5%
WACC
10.0%
ROIC − WACC
-10.5 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamental Analysis Criteria
Passed (10)
- Price CAGR 10.91%
- Gross Margin 46.4%
- Debt/Equity ratio
- Positive Free Cash Flow
- Current Ratio
- Revenue Growth 5Y 11.6%
- Analyst Consensus 62% Buy
- Earnings Surprise avg 19.0%
- Share Dilution -61.5%
- Piotroski F-Score 5/9
Failed (13)
- EPS shows upward trend
- ROIC -0.5%
- P/FCF 105.06
- P/B Ratio 4.11
- Operating Margin -0.9%
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- DCF valuation (Overvalued)
- ROE -2.9%
- Net Margin Trend -2.0% vs 2.3%
Unavailable (4)
- Dividend Payout NaN%
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
Mixed signals: some areas need attention
Earnings Quality
Low quality: investigate accounting
Share Dilution
Buying back shares. Shareholder friendly
Institutional Holdings
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Dr. Frank H. Laukien Ph.D. | Chairman, CEO & President | 65 |
| Mr. Gerald N. Herman CPA | Executive VP & CFO | 67 |
| Dr. Mark R. Munch Ph.D. | Corporate Executive VP and President of Bruker Nano Group & Corporate | 63 |
| Mr. Juergen W. Srega | President of Bruker Biosystems Group & Bruker Daltonics Division | 70 |
| Mr. Thomas M. Bures | Chief Accounting Officer | 50 |
| Mr. J. Brent Alldredge J.D. | Senior VP, General Counsel, Secretary & Global Head of Compliance | 50 |
| Dr. Wolfgang Pusch Ph.D. | President of Bruker Microbiology & Infection Diagnostics Group | - |
| Dr. Burkhard Prause Ph.D. | President and CEO of Bruker Energy & Supercon Technologies, Inc. | 58 |
Audit Risk
7
Board Risk
6
Compensation Risk
6
Shareholder Rights Risk
5
Part 2 · The price and when to enter
This part won't tell you whether the company is worth owning: it helps you choose when to buy it, once the fundamentals have convinced you. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Documents
- View document
Annual Report (10-K)
A yearly overview of the business, its financial results, and the risks it faces.
Filed on 2026-02-27
- View document
Quarterly Report (10-Q)
A snapshot of financial performance for the most recent three-month period.
Filed on 2026-08-05
- View document
Current Report (8-K)
An announcement of a major event, such as a leadership change or big news.
Filed on 2026-08-14
via SEC EDGAR
Income History
via SEC EDGAR
Latest News
Recent headlines for BRKR, sourced from Markets Gazette.